China Biologic Products, Inc. (NASDAQ:CBPO) has been given a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that cover the stock, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy recommendation.

Analysts have set a 1 year consensus price objective of $135.67 for the company and are expecting that the company will post $1.36 earnings per share for the current quarter, according to Zacks. Zacks has also assigned China Biologic Products an industry rank of 122 out of 265 based on the ratings given to its competitors.

A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of China Biologic Products from a “hold” rating to a “sell” rating in a research report on Friday, May 5th. Jefferies Group LLC reiterated a “buy” rating and issued a $140.00 price target on shares of China Biologic Products in a research note on Monday, June 12th. Goldman Sachs Group, Inc. (The) assumed coverage on shares of China Biologic Products in a research note on Tuesday, May 30th. They issued a “neutral” rating on the stock. Finally, BidaskClub cut shares of China Biologic Products from a “hold” rating to a “sell” rating in a research note on Sunday.

In related news, insider Zhijing Cbpo Liu sold 7,500 shares of the stock in a transaction dated Tuesday, May 9th. The shares were sold at an average price of $116.49, for a total value of $873,675.00. Following the sale, the insider now directly owns 10,969 shares of the company’s stock, valued at approximately $1,277,778.81. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 2.73% of the company’s stock.

Hedge funds have recently bought and sold shares of the company. Eqis Capital Management Inc. raised its stake in China Biologic Products by 51.3% in the first quarter. Eqis Capital Management Inc. now owns 3,220 shares of the biopharmaceutical company’s stock worth $322,000 after buying an additional 1,092 shares during the period. Oppenheimer Asset Management Inc. purchased a new stake in China Biologic Products during the first quarter worth $156,000. Azimuth Capital Management LLC raised its stake in China Biologic Products by 6.3% in the first quarter. Azimuth Capital Management LLC now owns 28,055 shares of the biopharmaceutical company’s stock worth $2,809,000 after buying an additional 1,660 shares during the period. Nordea Investment Management AB raised its stake in China Biologic Products by 15.5% in the first quarter. Nordea Investment Management AB now owns 13,200 shares of the biopharmaceutical company’s stock worth $1,322,000 after buying an additional 1,768 shares during the period. Finally, Geode Capital Management LLC raised its stake in China Biologic Products by 15.4% in the first quarter. Geode Capital Management LLC now owns 14,309 shares of the biopharmaceutical company’s stock worth $1,432,000 after buying an additional 1,906 shares during the period. 74.29% of the stock is currently owned by institutional investors.

Shares of China Biologic Products (NASDAQ:CBPO) traded down 1.37% during trading on Thursday, reaching $104.90. The company’s stock had a trading volume of 87,801 shares. China Biologic Products has a one year low of $96.99 and a one year high of $137.38. The firm’s 50-day moving average price is $108.72 and its 200-day moving average price is $108.88. The company has a market capitalization of $2.85 billion, a price-to-earnings ratio of 27.17 and a beta of 1.74.

TRADEMARK VIOLATION WARNING: “China Biologic Products, Inc. (CBPO) Receives Consensus Recommendation of “Strong Buy” from Brokerages” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/07/20/china-biologic-products-inc-cbpo-receives-consensus-recommendation-of-strong-buy-from-brokerages.html.

China Biologic Products Company Profile

China Biologic Products, Inc (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment.

Get a free copy of the Zacks research report on China Biologic Products (CBPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related companies with MarketBeat.com's FREE daily email newsletter.